VV119 / Vigonvita Life Sci - LARVOL DELTA

Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers (clinicaltrials.gov) - P1 | N=82 | Active, not recruiting | Sponsor: Vigonvita Life Sciences | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Oct 2026 | Trial primary completion date: Dec 2025 ➔ Oct 2026

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119 (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Jul 2026 ➔ Oct 2026 | Trial primary completion date: Jul 2026 ➔ Oct 2026

Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults (clinicaltrials.gov) - P2 | N=500 | Not yet recruiting | Sponsor: Vigonvita Life Sciences

New P2 trial • CNS Disorders • Psychiatry • Schizophrenia

Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119 (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Apr 2026 ➔ Jul 2026 | Trial primary completion date: Apr 2026 ➔ Jul 2026

Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119 (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Dec 2025 ➔ Apr 2026 | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Study of Food Effects of VV119 Capsules in Chinese Healthy Volunteers (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Vigonvita Life Sciences | Not yet recruiting ➔ Recruiting

Enrollment open

Study of Food Effects of VV119 Capsules in Chinese Healthy Volunteers (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Vigonvita Life Sciences

New P1 trial

Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119 (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Jul 2025 ➔ Dec 2025 | Trial primary completion date: Jul 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119 (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Vigonvita Life Sciences | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Psychiatry • Schizophrenia

Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119 (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Vigonvita Life Sciences

New P1 trial • CNS Disorders • Psychiatry • Schizophrenia

Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: Vigonvita Life Sciences | Trial completion date: Apr 2024 ➔ Dec 2024 | Trial primary completion date: Apr 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia